Phase I Trial of the LSD1 inhibitor sp-2577 in patients with relapsed or refractory Ewing Sarcoma:
Cost of Trial: $$$
Ewing sarcoma is an aggressive form of cancer that typically presents as a bone tumor in children and young adults. Approximately 20-30% of patients will be diagnosed with a metastatic form of the disease that unfortunately does not respond to systematic chemotherapy. LSD1 is a protein found in tumor cells and plays an important role in tumor cell growth and survival. Researchers with the Sunshine Project are testing the Seclidemstat (SP-2577), is an oral LSD1 inhibitor designed to block the activity of LSD1, which may, in turn, slow or stop the growth of tumor cells.
Current Amount Funded: $$$
Phase I Trial of the Blood-based biomarkers for minimal residual disease detection in pediatric sarcomas:
Cost of Trial: $$$
A cutting edge project that will collect blood samples from patients diagnosed with sarcoma, to test whether the detection of cell-free plasma tumor DNA (ptDNA) in the patient’s blood can better predict recurrence of disease when a patient is in radiographic remission. Having a blood-based test that can detect minimal residual disease in sarcomas can make an immediate impact as well as a lasting future impact on how we treat sarcomas.
Current Amount Funded: $$$
Phase I Trial of the Evolutionary inspired therapy for newly diagnosed, metastatic, Fusion Positive Rhabdomyosarcoma:
Cost of Trial: $$$
A clinical trial that offers patients the option of choosing between conventional chemotherapy or one of 3 evolutionary-based treatment models. The first two therapy models, first strike and second strike, both of which have the goal of making the cancer extinct. The third option, adaptive therapy, has the goal of containing the cancer versus eliminating it. By containing the cancer, the goal is for long term control of the cancer at an acceptable size while maintaining a high quality of life.
Current Amount Funded: $$$
Phase II Study of nab-Paclitaxel in Combination with Gemcitabine for Treatment of Recurrent/Refractory Sarcoma in Teenagers and Young Adults:
Cost of Trial: $$$
This trial will look at this combination of drugs and their ability to prevent the formation or growth of tumors in teenagers and young adults with relapsed or refractory osteosarcoma, Ewing sarcoma, rhabdomyosarcoma, and other soft tissue sarcomas.
Current Amount Funded: $$$
Phase IB/II Study to Evaluate the Safety, Feasibility, and Efficacy of Nivolumab or Nivolumab in Combination with Azacitidine in Patients with Recurrent, Resectable Osteosarcoma:
Cost of Trial: $$$
Relapsed osteosarcoma has a dismal prognosis. The main predictors of survival after osteosarcoma recurrence include the time to first recurrence, disease burden, and ability to achieve complete surgical remission after recurrence. Immunotherapy is a potentially promising option for the treatment of osteosarcoma. An even more promising strategy is to enhance the effectiveness of immunotherapy treatment by combing immunotherapy with Nivolumab with Azacitidine, a cytotoxic agent that prevents cells from reproducing or growing.
Current Amount Funded: $$$